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The first herpes virus to be described was types 1 and 2, 
whose denomination is herpes simplex 1 and 2 or HSV -1 and 
HSV -2. These viruses have specific biological characteristics, 
such as the ability to cause different kinds of diseases, as well 
as to establish host’s latent or persistent lifetime infections 
and also of being reactivated, causing lesions that can be 
located at the same site of the initial primary infection or 
close to it. It is suggested that this virus reactivation in the 
geniculate ganglion may be related to Bell’s palsy. In this 
situation, the viruses that would be latent in this ganglion, 
would suffer reactivation and replication, then be diffused 
through the facial nerve and its branches, among them 
the chorda tympani nerve, which by stimulating salivary 
secretion would enable the identification of the viral DNA 
in the patients’ saliva. Until recently, a great number of 
patients was diagnosed as holders of this kind of paralysis, 
named idiopathic or Bell’s palsy. With the introduction of 
the technique studying the viral DNA by Polymerase Chain 
Reaction (PCR), several authors have found herpes simplex 
virus type I DNA in the cerebrospinal fluid, in the lachrymal 
secretion, in the saliva and in the geniculate ganglia of 
patients with Bell’s palsy. Aim: observe the occurrence of 
herpes simplex type I virus using PCR technique in the saliva 
of patients with Bell’s palsy and relating it to the clinical 
evolution of these cases. Methodology: We evaluated 38 
patients with Bell’s palsy submitted to anamnesis, clinical 
and ENT examination and saliva sampling for viral DNA 
detection by PCR technique. The control group was ten 
normal adults. Results: We found positive viral DNA in 
11 cases out of the 38, which corresponded to 29% of the 
sample. This result was statistically significant if compared 
to the control group, in which we did not find any positive 
case. Conclusion: The end result was that the presence of 
HSV -1 in the saliva of patients with Bell’s palsy indicating 
that the viral reactivation can be the etiology of this disease. 
The detection of the virus in these patients’ saliva does not 
influence the disease prognosis.
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INTRODUCTION
Types 1 and 2 were the first herpes virus described 
(HHV-1 and HHV-2), called herpes simplex 1 and 2 or 
HSV-1 and HSV-2. These viruses bear particular biologic 
characteristics, such as the potential to cause different 
types of diseases, to establish latent or persistent infections 
during the host’s life time and that of being reactivated 
causing lesions that may be located on the site of the 
primary initial infection  or near it.
The lesions caused by these viruses were first 
documented by Hypocrates  (460/377 b.C.), who called 
them herpes, from reptile, because of the skin vesicles. 
But it was only in 1968, that two types of herpes virus 
- Simplex virus genus were classified on the basis of their 
biological and antigenic differences.  These observations 
were fundamental for clinical, serological, immunological 
and epidemiological studies that peaked at the establish-
ment of the anti-viral therapy, and it also demonstrated 
the genotypic and phenotypic differences among variants 
of HHV-1 and 2. 
The International Committee on Taxonomy of 
Viruses (ICTV) classified this virus in the Herpes viridae 
family, Alphaherpesvirinae subfamily, Simplex virus gen-
era, types 1 and 2.  Both HSV-1 and HSV-2 are made up 
of an electrodense core of 150-153 Kpb double linear 
DNA strains.  HSV-1 and 2 infect different cell types, such 
as fibroblasts, squamous and mucous cell epithelia, po-
larized cells of the cylindrical epithelium, glial cells and 
nerve endings.
These virus show the capacity to establish latent 
or persistent infection throughout its host’s life, chang-
ing the latency site according to its subfamily. The major 
characteristics of the alfa-herpesviridae family members 
is to establish latency in the sensory nerves. During this 
latency period, the viral DNA is not completely silent. 
None of the viral genes expressed during the lytic phase 
is detected.  However, some RNA called latency associated 
transcripts may be found in high levels.  In the same way, 
these viruses may show the reactivation mechanism, when 
the virus may be reactivated in peripheral tissues, and this 
could, at least in part, explain the virus transmission in an 
asymptomatic period. 
Clinically, most HSV-1 is isolated in herpetic lesions 
of the oropharynx.  After the acute or symptomatic phase 
of virus manifestation, it may remain latent in the sensitive 
ganglia neurons, as in the facial nerve case, the geniculate 
ganglion.  The viral reactivation in this site may cause an 
inflammatory process able to trigger a peripheral facial pa-
ralysis.  This is the main disease that affects the facial nerve 
and has broad etiology, where systemic, inflammatory and 
tumoral diseases, among other, may determine it4,5.
Clinically the peripheral Facial Paralysis is a dis-
ease characterized by the loss of muscle movement in 
half the face, generating a clear deformity during facial 
expressions. 
Until recently, a large number of patients was di-
agnosed as carriers of one type of this paralysis, the one 
called idiopathic or Bell’s paralysis.  These terms are still 
used in the literature to characterize those patients with 
acute signs of peripheral facial paralysis and without an 
etiological diagnosis defined even after conventional clini-
cal, laboratorial and image investigations4.
Starting on the 70’s, many studies tried to establish 
this disease etiology5,6,7.  Among them, many are the papers 
that present cases showing some positive serology for her-
pes simplex virus, varicella-zoster, mononucleosis, mumps, 
measles, among others7.  With the creation of the viral DNA 
study technique with the polymerase chain reaction (PCR), 
many authors found type I herpes simplex virus DNA in 
the facial nerve endoneurium fluid, CSF, tears, saliva and 
the geniculate ganglia of Bell’s palsy patients8,9,10.
Identifying HSV-1 DNA virus in all these circum-
stances indicate that the type 1 herpes simplex virus may 
very well be the major agent responsible for this periph-
eral facial paralysis (PFP)11-14.  In serial studies involving 
Bell’s PFP patients, Furuta et al.13 found 17% of HSV-1 
PCR positive cases in the saliva for a total of 176 patients 
investigated.  However, Abiko et al., in 16 patients, found 
5 (31%) positive tests. 
The goal is to detect type 1 herpes simplex virus by 
PCR in the saliva of Bell’s Peripheral Facial Paralysis pa-
tients, comparing them to a control group and correlating 
it to electroneurography and degree of paralysis results.
MATERIALS AND METHODS
The study was carried out in a tertiary University 
Hospital  and  was referred and approved by that institu-
tion Medical Ethics Committee. 
Selection of clinical cases
38 consecutive patients were assessed and diag-
nosed as carriers of Bell’s Peripheral Facial Paralysis ac-
cording to the following inclusion criteria:
a) Acute peripheral facial paralysis with symptoms 
starting up to seven days after they were first seen at the 
hospital;
b) Physical and otolaryngological exam without 
evidences of a determined cause for the PFP. 
The control group encompassed 10 normal 
adults. 
METHOD
a) Medical follow up
The patients were seen as they arrived at the medical 
facility, were then interviewed and went through general 
and otolaryngological physical exams. 
9BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY 72 (1) JANUARY/FEBRUARY 2006
http://www.rborl.org.br  /  e-mail: revista@aborlccf.org.br
b) Material harvest
In this visit, saliva was harvested from the patients’ 
mouth using a disposable sterile syringe without the nee-
dle.  The saliva was stored in a proper container for the 
PCR (EPENDORFF).
c) Lab exams
Tests were carried out in order to detect the HSV-1 
viral DNA through PCR using specific primers aforemen-
tioned for this virus. 
d) Statistical analysis
The results obtained both from the clinical and 
laboratorial views were statistically analyzed. 
RESULTS
38 patients with acute Bell’s PFP were assessed, 16 
males and 22 females. Of those, 11 (29%) had positive PCR 
for the HSV-1 virus in the first week of disease develop-
ment.  The positive PCR cases were divided in 5 females 
(23%) and 6 males (37%).
The age ranged from 6 to 71 years, and 12 of these 
patients were between 21 and 30 years. Table 1 shows 
cases distribution according to age and results for the 
HSV-1 PCR test.
We could see that in the assessed clinical cases, the 
stapedial reflex was not present in 21 cases and present in 
the other 13 cases.  Among PCR positive cases, 9 patients 
(80%) did not have this reflex while only 2 patients (20%) 
had the reflex present. 
Table 2 depicts the facial nerve electroneurography 
results according to the HSV-1 PCR test. 
Table 3 depicts the degree of facial paralysis ac-
cording to the House-Brackmann classification (1985) at 
the patient’s admission compared to the HSV-1 PCR test 
results.
As far as development is concerned, of the 38 pa-
tients assessed, 27 were discharged without sequelae and 
three remained in grade II of the House-Brackmann clas-
sification.  Two remained in grade V, three patients were 
decompressed and three did not have clinical follow up. 
Of the positive patients, three did not improve and 
one was referred to surgery, another remained in grade 
II and another, still, in grade V.
DISCUSSION
In the acute PFP the medical team has to act quickly 
in order to establish the most adequate diagnosis and treat-
ment for the patient and thus, avoid future facial motor 
sequelae. It is of fundamental importance to define the 
etiology both for treatment purposes and to provide a more 
accurate prognosis.  It is not always easy though, therefore 
it is important to carry out a careful clinical evaluation and, 
in many cases, a number of complementary tests.
Bell’s palsy in our settings is characterized for being 
a diagnosis of exclusion. A new situation is arising with 
modern lab techniques for viral investigation that is mak-
ing this current concept, which is around since the 90’s, 
broadly modified and the facial nerve involvement in the 
PFP is better assessed.
In this study, 29% of the Bell’s PFP cases had HSV-1 
positive test in their saliva.  This figure is greater than the 
one found by Furuta et al., who evaluated 176 patients. 
Compared to the results from Abiko et al., our data coin-
cide, although his sample was smaller (16 patients).  We 
may believe that these positive cases may have had a virus 
Tabela 1. Bell´s Palsy case distribution according to age range and 
the PCR result test for saliva HSV-1 in the first week of the disease 
- 2004.
Age (years)
#  PCR + cases 
n  (%)
# PCR –cases 
n (%)
# of cases 
assessed
0-10 0 3 (11) 3
11-20 2 (18) 5 (18) 7
21-30 3 (27) 9 (33) 12
31-40 1 (9) 4 (15) 5
41-50 3 (27) 3 (11) 6
51-60 1 (9) 2 (7) 3
61-70 0 1 (4) 1
71-80 1 (9) 0 1
Table 2. Distribution of facial nerve electroneurography results accord-
ing to PCR for HSV-1 in Bell’s Palsy cases.
EnoG (%)
#  PCR + cases 
n (%)
# PCR -cases 
n (%)
# cases 
0-20 2 (18) 4 (18) 6
21-40 3 (27) 6 (26) 9
41-60 4 (36) 2 (8) 6
61-80 0 9 (39) 9
81-100 2(18) 2 (8) 4
Table 3. Distribution of Bell’s Peripheral Paralysis Cases according to 
the degree of paralysis and the PCR test result for HSV-1.
GRADE # Cases 
PCR positive
# (%)
PCR negative
# (%)
II 2 0 2 (7)
III 10 1 (9) 9 (33)
IV 8 3 (27) 5 (19)
V 11 4 (36) 7 (26)
VI 7 3 (27) 4 (15)
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reactivation process as etiology. 
The establishment of this relationship may decisively 
influence the introduction of antiviral drugs in the treat-
ment of these patients.  HSV-1 was not influenced by the 
age factor in our investigation. 
This finding is not broadly discussed in the litera-
ture and does not uphold the idea that viral reactivation 
occurs more frequently in elderly patients.  One relevant 
fact was that we did not find the stapedial reflex in 80% 
of HSV PCR positive cases.  PCR negative cases had equal 
distribution as far as the presence or absence of this reflex 
is concerned.
Analyzing this fact, we can postulate that if the virus 
is reactivated in the geniculate ganglion, migrated through 
the facial nerve and reached the salivary gland (via chorda 
tympanis nerve), it is likely that there may have occurred an 
inflammatory process in the facial nerve tympanic-mastoid 
segment and, with that, involvement of its stapedial branch 
(reflex absence) happening more frequently.
As to facial nerve electroneurography, we did not 
observe significant difference of results in comparison 
with PCR positiveness for HSV-1 (Table 2).  Therefore, this 
virus did not cause greater nor less axonal involvement if 
compared to cases without HSV-1.
As to PFP degree, we observed that negative PCR for 
HSV-1 had a homogenous distribution  among grades II to 
IV.  In positive PCR cases, 63% presented grades V or VI. 
This would indicated that the virus causes greater neural 
involvement.  However, such data is not corroborated by 
facial nerve electroneurography findings. 
Another important fact is patient clinical evolution, 
assessed according to HSV-1 positiveness.  As we observed, 
positive or negative PCR HSV-1 did not influence patient 
recovery.  This fact was also observed by Furuta et al.13
CONCLUSION
HSV-1 present in the saliva of  Bell’s PFP patients 
tells us that viral reactivation may be the very etiology of 
this disease. Detecting the virus in the saliva does not alter 
the disease prognosis.
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Stapedial Reflex: Right: ( ) Absent ( ) Present -
( ) with recruitment
Left: ( ) Absent ( ) Present - ( ) with recruitment
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( ) Tumoral:
( ) Metabolic:
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( ) Steroid: Predinisone (60 mg/day- morning dose for 3 
days – weaning until 10mg/day)
( ) NHAID: Nimesulide (1 pill or  1 drop/kg a each 12 hs 
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Chart 1. Irmandade da Santa Casa Misericórdia de S.Paulo  - Departa-
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